Chondroitin sulfate proteoglycan 4 (CSPG4) represents another emerging target for GBM CAR T-cells with high expression of this antigen in two-thirds of GBM patient specimens with little expression on normal tissues (170). Here, CSPG4 is linked to glioblastoma.